SEC For	m 4																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								SHIP	Estim	Estimated average burden		3235-0287 :n 0.5	
1. Name and Address of Reporting Person [*] Sands Stephen H.					2. Issuer Name and Ticker or Trading Symbol <u>BICYCLE THERAPEUTICS plc</u> [BCYC]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024								(give title		Other (below)	specify	
C/O BICYCLE THERAPEUTICS PLC BLOCKS A & B, PORTWAY BUILDING					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) CAMBRIDGE X0 CB21 6GS					Form filed by More than One Reporting Person									rting				
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Nor	n-Deriv	ative Se	curities Ac	quired,	Dis	posed o	of, o	or Bene	eficial	y Owned					
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I						2A. Deemed Execution Date if any (Month/Day/Yea	Code	Transaction Code (Instr.					4 and Securities Beneficiall Owned Fo		Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Ordinary Shares 02/20.						.024			12,000 A		Α	\$0 ⁽²⁾	12,000		D			
		٦				urities Acq ls, warrants							Owned					
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any		Date, T	ansaction of E ode (Instr. Derivative (I		Expiratio	5. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares		
Stock Option (right to buy)	\$22.5	02/20/2024	A		24,000		(3)	02/20/2034	Ordinary Shares	24,000	\$0	24,000

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027.

2. Each RSU represents a contingent right to receive one ordinary share.

3. This option shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027.

/s/ Jason Minio, Attorney-in-02/21/2024

D

** Signature of Reporting Person Date

Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.